Gaceta Médica de México

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Gaceta Médica de México >Year 2002, Issue S1

Ambriz-Fernández R, Malagón-Martínez A, Zapata-Menchaca MG, Bravo-Lindoro AG, Indrikovs AJ
Innovations in Transfusional Medicine

I. National Consensus for Use of Blood and Its Components.
II. Chagas Disease Panorama in Mexico.
III. Leukoreduction. What For? When? How?
IV. Therapeutic Apheresis: Accepted Indications in Clinical H

Gac Med Mex 2002; 138 (S1)

Language: Español
References: 45
Page: 35-46
PDF: 79.91 Kb.

Full text

Text Extraction

No abstract

Key words: No keywords


  1. Norma Oficial Mexicana NOM-003-SSA2-1993. Para la disposición de sangre humana y sus componentes con fines terapéuticos. México: Diario Oficial de la Federación. 18 de julio de 1994.

  2. American Society of Anesthesiologists Task Force on Blood Component Therapy. Practice guideline for blood component therapy. Anesthesiology 1996;84:732-47.

  3. Mintz DP. Transfusion therapy: clinical principles and practice. 1st ed. Bethesda, MD, USA: American Association of Blood Banks; 1999.

  4. WHO. Developing a national policy and guidelines on the clinical use of blood-recommendation. Geneva, Switzerland: December 1988.

  5. Indicaciones para la práctica transfusional en pediatría. Instituto Mexicano del Seguro Social. Dirección de Prestaciones Médicas. Coordinación de Atención Médica; 2001.

  6. Blajchman MA, Hume H, Blanchette VS. Symposium of neonatal transfusion. Transfus Med Rev 1995;9:185-287.

  7. Menitove JE, Snyder ED. Platelet transfusion practice: time for renewed consensus. Transfusion 1998;38:707-9.

  8. Contreras M. Final statement from the consensus conference on platelet transfusion. Transfusion 1998;38:796-7.

  9. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer. Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1519-38.

  10. NIH Consensus Development Conference. Platelet transfusion therapy. JAMA 1987;257:1777-80.

  11. NIH Consensus Development Conference. Fresh frozen plasma: indications and risk. JAMA 1985;253:551-3.

  12. Contreras M et al. Guidelines for use of fresh frozen plasma. British Committee for Standards in Haematology, Working Party of the Blood Transfusions Task Force. Transfus Med 1992;2:57-63.

  13. The United States Pharmacopeial convention, Inc. Hemophilia management. Transfus Med Rev 1998;12:128-40.

  14. College of American Pathologist. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate and platelets. JAMA 1994;271:777-8.

  15. Word Health Organization. Division of Control of Tropical Diseases. Control of Chagas Disease. Technical Report series 811. Geneva , Switrerland: WHO; 1991.

  16. Word Health Organization. Division of Control of Tropical Diseases. Chagas Disease Elimination. Technical Report series 811. Switrerland: WHO; 1998.

  17. Velasco CO, Guzmán BC. Importancia de la enfermedad de Chagas en México. Rev Latiamer Microbiol 1986;28-275-283,

  18. Velasco CO, Ramírez J, et al. La enfermedad de Chagas en Jalisco. Rev. Mex Parasitol 1989;2:29-32.

  19. Goldsmith K, Reyes G, Cedeño F. Bol Ofici Panam 1971:500-516.

  20. Vallejo A, Reyes A. Tripanosomiasis Americana. ¿Un problema sociomédico en Mexico? Arch Inst Cardiol Méx 1996;66:95-97.

  21. Norma Oficial Mexicana NOM-SSA2-1993, para la disposición de sangre humana y sus componentes con fines terapéuticos. Diario Oficial de la Federación 18 de julio 1994.

  22. Ramos E, Monteón P, Reyes L. Salud Pública Mex 1993; 35:56-64.

  23. Toy J, Salazar S, Ontiveros A, et al. Bol Sanit Panam 1987;102: (4).

  24. Goldsmith RS, Zárate RJ, ZárateLG, et al .Bol Sanit Panam 1986:100(2).

  25. Velasco C, Valdespino J, et al. Salud Pública Mex 1992.34:186-196.

  26. Fuenmayor A, Fuenmayor P. Muerte súbita en pacientes con miocarditis chagásica. Arch Inst Cardiol Méx 1996; 66:157-161

  27. Guzmán C, García L, Florián J, Ramírez C, Guerrero S, Velasco C. Riesgo de transmisión de T. cruzi por transfusión de sangre en México. Panam J Public Health 1998;4:94-98.

  28. Janatpour K, Holland P. Blood support for pediatric surgery. Indian J Paediatr 2001; 68(2):159-165.

  29. Goognough L. Universal leukoreduction of cellular blood components in 2001? Am J Clin Pathol 2001;115:674-677.

  30. Sweeney JD. Universal leukoreduction of cellular blood components in 2001? Yes. Am.J. Clin .Pahol 2001; 115:666-673.

  31. Strong M. Leukocyte reduction of blood components. Blood Bulletin America’s Blood Cent 1998:1:2.

  32. Lane T, Kenneth C, Anderson M. et al. Leukocyte reduction in blood component therapy. Ann Intern Med 1992;117:151-162.

  33. Bordin J, Heddle N, Blajchman M. Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994;84:6:1703-1721.

  34. Miller J. Mintz P. The use of leukocyte reduced blood components. Hematol Oncol Clin North Am 1995;9:69-90.

  35. Ratko T, Cummings J, Oberman H, et al. Evidence –based recommendations for the use of WBC-reduced cellular blood components. Transfusion 2001;41:1310-1319.

  36. Rodrigues A. Tipos de desleucocitaçâo: prearmazenamento, em laboratorio e de cabeceira. Conferencias del curso residencial ibérico de la ESTM. Asociación Española de Hematología y Hemoterapia, Sociedad Española de Transfusión Sanguínea, Associaçâo Portuguesa de Imuno –Hemoterapia (APIH) Lisbom, Portugal 2001:135-153.

  37. FDA-CBER: Recommendation and licensure requirements for leukocyte reduced blood products. FDA-memorandum, May 26, 1996

  38. Council of Europe Guidelines: guide to the preparation, use and quality assurance of blood components 4th ed. Strasbourg, France: Council of Europe Publishing, 1992.

  39. Miller PJ, Aubuchon JP. Leukocyte-reduced and cytomegalovirus-reduced-risk blood components. In: Mintz PD, ed. Transfusion therapy: Clinical principles and practice 1999. AABB. 313-339

  40. Uhlmann JE, Isgriggs E, et al. Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reaction. Transfusion 2001;41:997-1000.

  41. García de Villaescusa R. Métodos de contaje de células residuales: control de calidad. Conferencias del curso residencial ibérico de la ESTM. Asociación Española de Hematología y Hemoterapia, Sociedad Española de transfusión sanguínea, Associaçâo Portuguesa de Imuno Hemoterapia (APIH). Lisbon, Portugal: 2001. p. 160-161.

  42. Dumont LJ, Dzink WH, Rebulla H,et al. Practical guidelines for process validation and process control of white cell-reduced blood components: report of the Biomedical Excellence for Safer Transfusion (BEST) working party of the International Society of Blood Transfusion (ISBT). Transfusion 1996:36:11-20.

  43. American Society for Apheresis. Organizational guidelines for therapeutic apheresis facilities. J Clin Apheresis 1996;11:42-5.

  44. Clinical applications of therapeutic apheresis. McLeod BC, guest editor. J Clin Apheresis 2000;15(v. 1-2).

  45. Technical Manual, 13th ed. American Association of Blood Banks. Ch. 6. Vengelen-Tyler V, editor 1999. p. 129-147.

>Journals >Gaceta Médica de México >Year 2002, Issue S1

· Journal Index 
· Links 

Copyright 2019